Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan Effect on Zongertinib Pharmacokinetics in Healthy Males
NCT07649941Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zongertinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from zero to infinity at 8 days and Maximum measured concentration at 8 days. Started Jun 2026; status: completed.
02
Drugs
zongertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07649941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07649941.